The need for an integrated pharmacological response to the treatment of HIV/AIDS and depression
- 13 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 22 (9), 1179-1192
- https://doi.org/10.1080/14656566.2021.1882419
Abstract
Introduction: The coexistence of depression and HIV infection affects more than 9 million people worldwide. A literature review revealed a large gap regarding the pharmacotherapy of depression among patients dually diagnosed with HIV and depression. Areas covered:In this review, the authors covered the various dimensions of deploying integrated pharmacological treatment of HIV/AIDS and depression. This topic was addressed in two ways; first, the direct results of integrated pharmacotherapy in syndemic patients; second, the indirect effects of the integrated model on other outcomes of HIV care. Expert opinion: An integrated pharmacological response to the treatment of HIV and depression can bring substantial benefits to HIV outcomes and reduce the burden of both diseases. The direct advantages regarding pharmacological response to the treatment of depression along with HIV care are improving adherence to antiretroviral therapy, optimizing pharmacotherapy, minimizing drug interaction, and prevention of additive adverse drug reactions. Furthermore, in some cases, medication can target both depression and other neuropsychiatric or somatic comorbidities among people living with HIV/AIDS. The integrated pharmacotherapy also has some potential indirect advantages on HIV care outcomes like minimizing loss of care, reducing ongoing HIV transmission, and improving the outcomes of both diseases.Keywords
Funding Information
- This manuscript was not funded
This publication has 123 references indexed in Scilit:
- A Qualitative Analysis of the Effects of Depression and Antidepressants on Physical and Work Functioning among Antiretroviral Therapy Clients in UgandaJournal of the International Association of Providers of AIDS Care (JIAPAC), 2013
- Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: A randomized controlled trial.Journal of Consulting and Clinical Psychology, 2012
- The Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy Among Adult Persons Living with HIV/AIDS: A Systematic ReviewAIDS and Behavior, 2012
- Correlates of Antiretroviral and Antidepressant Adherence Among Depressed HIV-Infected PatientsAIDS Patient Care and STDs, 2012
- Suicide and antidepressants: What current evidence indicatesMens Sana Monographs, 2012
- Safety Considerations in Drug Treatment of Depression in HIV-Positive PatientsDrug Safety, 2011
- Selective Serotonin Reuptake Inhibitor Suppression of HIV Infectivity and ReplicationPsychosomatic Medicine, 2010
- Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major DepressionBiological Psychiatry, 2009
- An instrumental variables evaluation of the effect of antidepressant use on employment among HIV‐infected women using antiretroviral therapy in the United States: 1996–2004Health Economics, 2009
- Antidepressant Treatment and Adherence to Combination Antiretroviral Therapy among Patients with AIDS and Diagnosed DepressionPsychiatric Quarterly, 2007